NewsNovo
Novartis shares shed 9% on Tuesday after results from the company's del-desiran drug trial disappointed investors.
That drop came alongside two other trial setbacks reported in the same session, and the tension the tape is sitting with now is whether this is a compound-level miss or a pipeline-level problem.
The case for a pipeline concern rests on the clustering. Del-desiran is the named catalyst, but three trial setbacks arriving in a single day does not read as routine variance.
When results disappoint together rather than in isolation, the read-through tends to settle on R&D execution rather than on the peculiarities of any one compound. The counterargument is worth stating plainly.
Keep reading